Assessment of direct medical cost using cost of illness analysis in patients with dengue fever - Retrospective study

Background: A drug therapy problem is any undesirable event experienced by a patient which involves, or is suspected to involve drug therapy and that interferes with achieving the desired goals of therapy. Drug Therapy Problems (DTPs) can lead to ineffective pharmacotherapy and may cause drug-related morbidity and mortality.Objective: The study aimed to estimates the direct medical cost of illness caused by the drug morbidity or mortality related to NSAID utilization in a community pharmacy setting at Medan, Indonesia.Method: Thisstudy used 7 (seven) categories probabilities and costs associated with the therapeutic outcomes to estimate the direct medical cost of illness resulting from morbidity related NSAIDs utilization. Direct non medical costs, indirect costs, and intangible costs related to drug-related-morbidity and mortality were not valued in this cost-of-illness analysis.The duration of the study was from July 2009 to October 2010.Result: The patient that experienced NSAIDs-related morbidity estimated to spend Rp.467.848,- each and Rp.11.696.200,- in total to managing the morbidity. Every Rp.1,- spent on NSAIDs therapy, an additional Rp.1,45,- was estimated to spent in managing morbidity related NSAIDs utilization.Conclusion: This result showed the cost of illnessrelated morbidity of NSAIDs utilization exceeds the cost of the medications themselves

Download Full-text

Cost of Illness of Malaria in Coastal Karnataka, India

JOURNAL OF COMMUNICABLE DISEASES ◽

10.24321/0019.5138.202122 ◽

2021 ◽

Vol 53 (02) ◽

pp. 28-34

Author(s):

Affan K ◽

Keyword(s):

Direct Medical Cost ◽

Cost Of Illness ◽

Medical Cost ◽

Secondary Data ◽

Cross Sectional Study ◽

Public Healthcare ◽

Service Utilisation ◽

District Health ◽

Cross Sectional ◽

The Cost

Background: Malaria is one of the major health issues in developing and underdeveloped countries. It is considered to be one of the main reasons for morbidity and mortality. This study intends to estimate the cost of illness of malaria at the household level and health service utilisation pattern for malaria treatment in coastal Karnataka. Materials and Methods: It was a secondary data-based cross-sectional study comprising people suffering from malaria during the period from September to December 2016. Result: The median gross total cost of illness (a single episode of malaria) was 4,000 INR, the median direct medical cost was zero, and the median direct non-medical cost was 100 INR. The majority of individuals (92.2%) took treatment from public healthcare sectors. Conclusion: The effective implementation of anti-malarial interventions by the District Health Authority, District Vector Borne Disease Control Office, and treatment from public health sectors resulted in negligible direct medical cost which made a remarkable reduction in the cost of illness of malaria.

Download Full-text

The Trend of Direct Medical Cost of Meliodiosis Patients in Kedah: A Retrospective Study from 2014 to 2017

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s286283 ◽

2021 ◽

Vol Volume 13 ◽

pp. 155-162

Author(s):

Kamaruddin Mardhiah ◽

Nadiah Wan-Arfah ◽

Nyi Nyi Naing ◽

Muhammad Radzi Abu Hassan ◽

Huan-Keat Chan ◽

...

Keyword(s):

Retrospective Study ◽

Direct Medical Cost ◽

Medical Cost

Download Full-text

ANALISIS COST OF ILLNESS PENYAKIT HIPERTENSI DI RUMAH SAKIT UMUM DAERAH PRAYA, NTB

AL ULUM JURNAL SAINS DAN TEKNOLOGI ◽

10.31602/ajst.v6i2.5226 ◽

2021 ◽

Vol 6 (2) ◽

pp. 104

Author(s):

Aris Fadillah ◽

Juwita Ramadhani ◽

Karina Erlianti ◽

Hasniah Hasniah

Keyword(s):

Direct Medical Cost ◽

Cost Of Illness ◽

Medical Cost ◽

High Prevalence ◽

Hypertensive Crises ◽

Stage 1 ◽

The Cost ◽

Heath Care ◽

Antihypertensive Treatments

The high prevalence of hypertension and the long-term of antihypertensive treatments required are the main reasons for the need of economic analysis on the costs of hypertensive treatment. This study aims to quantify direct medical cost of hypertension. This study uses retrospective cost of illness analysis in descriptive observational design with heath care perspective. Data were collected from the hospital’s management information system, patient's prescriptions and patient's medical records. Fifty-eight patient’s data were analyzed. Direct medical cost of the patient without comorbidities in stage 1 hypertension was Rp 535,660 ± 100,681, stage 2 hypertension was Rp 381,940 ± 126,423 and hypertensive crises was Rp 456,241 ± 197,959. Direct medical cost of the patients with comorbidities in stage 1 hypertension was Rp 398,750 ± 240,542, stage 2 hypertension was Rp 486,227 ± 241,136 and hypertensive crises was Rp 425,816 ± 140,898. Direct medical costs for patients with compelling indications in stage 1 hypertension was Rp 512,810 ± 152,661, stage 2 hypertension was Rp 444,183 ± 109,162 and hypertensive crises was Rp 410,364 ± 80,388. Cost for drugs was represented as the largest component of direct medical cost (37.49%) followes by cost for ward (26.54%), medical treatment fee (15.88%), medical support fee (9.05%), doctor visit fee (8.12%) and service fee (2.91%). The hypertension's stage, comorbidities and compelling indications are not affecting the cost of therapy. The rational use of drugs will decrease the cost of hypertension treatment.

Download Full-text